Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1739]

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally...

Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use...

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )

Trastuzumab emtansine improves overall survival versus treatment of physician's...

Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response...

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Editor's choice for December 2015

Prof Gordon McVie - ecancer Editor

Editor's choice for December 2015 ( Prof Gordon McVie - ecancer Editor )

Treatment outcomes in patients with invasive breast cancer treated with...

Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging ( Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA )

Novel estrogen receptor-targeting agent represents ‘quantum leap’

Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA

Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )

Ductal carcinoma in situ: Anastrozole versus tamoxifen

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA

Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )

Update on management of the axilla

Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA

Update on management of the axilla ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )

Higher local recurrence after skin-sparing than simple mastectomy for DCIS

Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom

Higher local recurrence after skin-sparing than simple mastectomy for DCIS ( Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom )

More from ecancer